Please ensure Javascript is enabled for purposes of website accessibility

Why Celldex Therapeutics Stock Is Tanking Today

By Keith Speights - Updated Mar 29, 2021 at 12:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech reported interim results from a phase 1b study.

What happened

Shares of Celldex Therapeutics (CLDX 0.83%) were tanking 34.1% as of 11:56 a.m. EDT on Monday. The big decline came after Celldex announced interim results from a phase 1b study of CDX-0159 in treating patients with chronic inducible urticaria (CIndU), severe hives that affect around 0.5% of the population.

So what

Celldex reported that eight of the 10 patients who were assessed for at least 15 days after treatment with CDX-0159 experienced a complete response. One of the patients experienced a partial response. That sounds like great news, so why did the biotech stock sink?

It could be that investors are concerned about the safety profile for CDX-0159. Celldex stated that the drug "was generally well-tolerated." However, the company also said that one patient experienced a severe reaction with a "brief loss of consciousness, followed by shaking and sweating." This patient was treated with antihistamines and steroids, and recovered quickly.

Two scientists in a lab with one looking through a microscope

Image source: Getty Images.

Marcus Maurer, professor of dermatology and allergy at Charite-Universitatsmedizin in Berlin and lead investigator for the study, didn't seem to share such concerns. He stated, "As a physician, it is exciting to see such high complete response rates, which are made even more noteworthy by the fact that the responses are developing rapidly after treatment and are coupled with a well-tolerated safety profile to date."

Celldex Therapeutics CEO Anthony Marucci also was positive about the interim data, stating, "The interim results reported today further reinforce our enthusiasm for CDX-0159."

Now what

The company expects to complete testing of additional cohorts in the phase 1b study over the next few weeks. Celldex plans to report updated results later in the near future, probably at a medical conference this summer. It also should announce results from a phase 1b study in chronic spontaneous urticaria by the end of 2021.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celldex Therapeutics, Inc. Stock Quote
Celldex Therapeutics, Inc.
CLDX
$29.16 (0.83%) $0.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.